Prof. Rong Tao 陶荣
Chief Physician, Professor
Department of Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai
Public profile Compiled from public listings and PubMed. We do not work directly with this doctor, but we can find a specialist in this field to review your case.
Get a specialist opinionClinical focus: Diagnosis and treatment of lymphoma, with a focus on advanced or relapsed/refractory NK/T-cell lymphoma, high-risk diffuse large B-cell lymphoma, peripheral T-cell lymphoma, and follicular lymphoma.
Dr. Tao holds an MD from the University of Hong Kong (2008) and serves as Director of the Lymphoma Department at Fudan University Shanghai Cancer Center. Research focuses on NK/T-cell lymphoma therapies, including GELAD and MEDA regimens, and clinical trials for BTK, PI3K, PD-1, and PD-L1 inhibitors in relapsed lymphomas.
Professional roles
- Vice Chair, Lymphoma Professional Committee, Shanghai Anti-Cancer Association
- Member, Lymphoma Professional Committee, China Anti-Cancer Association
- Standing Committee Member, Translational Medicine Committee, China Medical Education Association
- Standing Committee Member, Integrated Rehabilitation Professional Committee for Hematologic Tumors, China Anti-Cancer Association
Name order: in Chinese the family name comes first (Tao Rong). Papers usually list the name as Rong Tao or Tao R.
Selected publications
21 papers on PubMed matched by name and affiliation; 5 as first or senior author since 2016. Most recent first- or senior-author papers:
- Oncologist, 2026 (senior author): Selinexor plus tislelizumab in patients with relapsed/refractory natural killer/T-cell lymphoma after failure of PD-1 blockade: the phase 1b TOUCH trial. PubMed 42438166
- Leuk Lymphoma, 2026 (senior author): Clinicopathologic spectrum and outcomes of primary ovarian lymphoma: a retrospective case series. PubMed 42251697
- Blood Adv, 2026 (senior author): Sintilimab, pegaspargase, and anlotinib as induction therapy for advanced-stage NKTCL: a multicenter phase II study. PubMed 41774854
- Oncologist, 2024 (first author): Selinexor With Anti-PD-1 Antibody as a Potentially Effective Regimen for Patients With Natural Killer/T-Cell Lymphoma Failing Prior L-Asparaginase and PD-1 Blockade. PubMed 37616529
- iScience, 2023 (senior author): Targeting Bcl-xL is a potential therapeutic strategy for extranodal NK/T cell lymphoma. PubMed 37539026
See the full PubMed search. Automatic matching can miss papers or include a namesake at the same hospital. This name is shared by other researchers, so we checked that most papers list this doctor's hospital and department.
This profile has not been reviewed by the doctor. How we build this directory.
Want a specialist to review your case?
Send your records. We find a specialist in this field who can review your case and write a treatment plan with a cost estimate.
Get a specialist opinion